The Swiss pharma company Novartis ranks in the top 10 of pharma companies, and boasts drugs ranging from Ritalin and Lamisil to clozapine, Diovan and Gilenya. It also owns the generic giant Sandoz. Unlike its competitor, GlaxoSmithKline, Novartis did not offer free flu vaccines during the H1N1 flu epidemic.

In March 2011, Novartis gained FDA approval for Gilenya, its multiple sclerosis drug. The nod came on the heels of a narrower EMA approval, which grants second-line treatment status. According to experts, the drug could be worth $3 billion in annual sales as the first oral MS drug on the market.

Novartis purchased the remaining portion of eye care company Alcon in a $12.9 billion deal at the end of 2010, marking the end of one of the biggest battles in biopharma. Although many analysts predicted heavy layoffs in 2010 from the company, only 1,400 jobs were cut in December 2010, with the disclaimer that more could be on the way as Novartis, like others in the industry, analyzes its efficiency.



Latest Headlines

Latest Headlines

Top 10 pharma companies in social media

Social media success in consumer marketing has advanced beyond counting fans and followers. Today it's all about shares, retweets and links that indicate real consumer engagement with brands....

Novartis, PPD conduct clinical pilot study using medical device connectivity via a smartphone app

Startup Clinical Ink said that it's in the midst of a pilot clinical study that incorporates medical device data that's collected through a smartphone app with biopharma Novartis and contract research organization PPD. The trial incorporates medical device connectivity that's provided by Clinical Ink and powered by Qualcomm's 2net Mobile Platform.

Look out, Teva--Novartis' Copaxone generic is off to a speedy start

The launch for Glatopa, the new generic of Teva's Copaxone from Novartis' Sandoz, is still in the very early going. But so far, things look good--very good.

For Entresto rollout, Novartis marketing mixes tried-and-true with new-and-different

With all the excitement about Novartis' new heart failure drug Entresto, the usual question that follows an FDA approval--how will they actually sell it--might seem irrelevant. But the former LCZ696's path to blockbuster sales isn't without its obstacles, and the Swiss drugmaker isn't leaving much to chance.

Novartis' Sandoz puts India plant on chopping block

Novartis CEO Joe Jimenez said in March the company would have another go at significant cost cuts in the wake of its asset swap with GlaxoSmithKline. Manufacturing was one area where it expected to tighten up, and a plant in India is now on the chopping block along with 170 jobs.

Novartis' pay-for-performance Entresto plan has its critics--Express Scripts' Miller among them

Novartis has said it's planning to offer an outcomes-based plan for its new blockbuster-in-the-making to secure payers' favor. But skeptics see some kinks in the plan--and the CMO at leading PBM Express is one of them.

UPDATED: Novartis nabs early FDA approval for 'megablockbuster' Entresto

It was a hotly anticipated pipeline drug. Now, Novartis' heart failure remedy Entresto is a hot new approval. The FDA gave its blessing 6 weeks early, and now the former LCZ696 can get ready to roll.

UPDATED: FDA OKs Novartis' megablockbuster heart failure drug Entresto

The FDA has approved Novartis' big 2015 blockbuster, the heart failure drug Entresto, better known in development circles as LCZ696.

Novartis steps into wearables with app for Apple Watch, Android Wear

Novartis has opened a new front in its push into digital health. The latest move sees the Big Pharma bring its navigation app for visually impaired people to Apple and Google's smartwatch platforms.

Fast-growing Celgene snaps up Merck's abandoned NJ campus

Out with the old guard, in with the new. In another sign that Big Biotech is elbowing into the top levels of pharma, Celgene has agreed to buy Merck & Co.'s old campus in Summit, NJ, adding the sprawling 1.3-million-square-foot complex to its already growing operations in the city.